ArticlePulmonary therapy2026
Bronchiectasis Treatment Goals, Unmet Needs, and Emerging Therapies: A Podcast.
Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiectasis is a chronic and progressive inflammatory lung disease characterized by dilated airways, impaired mucociliary clearance, recurrent infections, and inflammation. In this podcast, we discuss the heterogeneous causes and complex pathophysiology of bronchiectasis, reviewing the therapeutic tools we currently have available to target aspects of the vicious vortex that drives disease progression. Patient evaluation involves identifying underlying causes such as autoimmune diseases or immune deficiencies, conducting sputum cultures for bacteria, fungi, and mycobacteria, and performing pulmonary function tests. The primary objectives of treatment are to alleviate symptoms, reduce burdensome exacerbations, enhance quality of life, and slow disease progression, requiring shared decision-making to align clinical and patient priorities. Effective management necessitates a multimodal approach to address all aspects of pathophysiology including airway obstruction, infection, and inflammation. An unmet need remains to fully address the inflammation, which is predominantly neutrophilic, driving bronchiectasis. Emerging therapies that directly target dysregulated neutrophilic inflammation via inhibition of the enzyme dipeptidyl peptidase 1 (DPP1) reduce neutrophil serine protease (NSP) activity. Brensocatib, an oral, once-daily DPP1 inhibitor, was recently approved by the FDA and is indicated in the USA for the treatment of noncystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older. In the phase 3, 52-week ASPEN trial, brensocatib significantly reduced exacerbation burden, and the 25-mg dose reduced lung function decline and nominally significantly improved patient-reported symptoms compared with placebo. Additional therapies in development include other DPP1 inhibitors (verducatib and HSK31858) and drugs targeting phosphodiesterase 3/4 inhibition (ensifentrine) and anti-interleukin-33 (itepekimab). Overall, the future is promising for patients with the historically neglected and underdiagnosed disease bronchiectasis, with growing awareness and new therapeutic tools becoming available. Podcast (MP4 81554 KB).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.